# US 2021/0330867 A1 · Temperature sensitive composition for tissue adhesion prevention and application thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0330867 A1
- Document ID: US20210330867A1
- Status: Published application
- Kind: A1
- Application number: 17/239,092
- Filed: 2021-04-23
- Published: 2021-10-28
- Earliest claimed: 2020-04-24
- Assignees: Pro-View Biotech Co., Ltd.
- Applicants: Pro-View Biotech Co., Ltd.
- Inventors: Yu-Chia CHANG; Yunn-Kuen CHANG; Wen-Yen HUANG; Ging-Ho HSIUE; Hsieh-Chih TSAI; Shuian-Yin LIN; Nai-Sheng HSU; Tzu-Yu LIN
- Web page: https://patentgrep.com/patent/US20210330867A1

## CPC

- C08G 65/33306: {acyclic}
- C08G 81/00: Macromolecular compounds obtained by interreacting polymers in the absence of monomers, e.g. block polymers (involving only carbon-to-carbon unsaturated bond reactions C08F299/00 {; polyester-amides C08G69/44; polyester-imides C08G73/16; polyamides-imides C08G73/14; block- or graft polymers containing polysiloxane sequences C08G77/42})
- A61K 31/337: having four-membered rings, e.g. taxol
- A61K 47/34: Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence)
- A61L 31/041: {Mixtures of macromolecular compounds}
- A61L 31/06: obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds {(A61L31/041 takes precedence)}
- A61L 31/16: Biologically active materials, e.g. therapeutic substances {(A61L31/047 takes precedence)}
- C08G 65/3344: {containing oxygen in addition to sulfur}
- C08L 71/02: Polyalkylene oxides
- A61L 2300/216: with other specific functional groups, e.g. aldehydes, ketones, phenols, quaternary phosphonium groups
- A61L 2300/416: Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
- A61L 2300/424: Anti-adhesion agents
- C08G 2650/58: Ethylene oxide or propylene oxide copolymers, e.g. pluronics
- C08G: MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- C08L: COMPOSITIONS OF MACROMOLECULAR COMPOUNDS (compositions based on polymerisable monomers C08F, C08G; artificial filaments or fibres D01F; textile treating compositions D06)

## Abstract

The present invention relates to a composition comprising an amino acid-modified polymer, a carboxypolysaccharide, and may further include a metal ion for anti-adhesion and vector application. More specifically, the invention relates to a thermosensitive composition having enhanced mechanical and improved water-erosion resistant properties for efficiently preventing tissue adhesions and can serve as a vector with bio-compatible, bio-degradable/absorbable, and in-vivo sustainable properties.

## Claims

### Claim 1

A composition comprising a polymer, and a carboxypolysaccharide, wherein the polymer having any one structure of the following formula (I):
or a combination thereof,
wherein:
POLY is a triblock copolymer of poly(ethylene oxide)(PEO)-poly(propylene oxide)(PPO)-poly(ethylene oxide)(PEO);
m and n are independently from each other 0 or 1, wherein m and n cannot be 0 simultaneously; and
AA is an amino acid residue, where its amino group directly binds to the chain-end of the POLY to form carbamate (O—C(═O)—NH) linkage.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the carboxypolysaccharide is one or more selected from the group consisting of carboxymethylcellulose (CMC), carboxyethylcellulose, hyaluronic acid (HA), alginate, carboxymethyl chitosan, pectin, carboxymethyl dextran, heparin sulfate, and chondroitin sulfate.

### Claim 3 (depends on 1)

The composition of claim 1, wherein POLY has an average molecular weight ranging from 1,000 to 20,000 Daltons.

### Claim 4 (depends on 1)

The composition of claim 1, wherein any one of the polymer or the combination thereof is in an amount of 5% to 30% by weight of the composition.

### Claim 5 (depends on 1)

The composition of claim 1, wherein the carboxypolysaccharide has a molecular weight in a range of 50 kg/mol to 4,000 kg/mol.

### Claim 6 (depends on 1)

The composition of claim 1, wherein the content of the carboxypolysaccharide is in an amount of 0.1% to 20% by weight of the final composition.

### Claim 7 (depends on 1)

The composition of claim 1, wherein POLY is selected from the group consisting of Pluronic F-127 (PF127), Pluronic F-68 (PF68) and Pluronic L-35 (PL35).

### Claim 8 (depends on 1)

The composition of claim 1, wherein the amino acid residue is selected from the groups consisting of hydrophobic amino acids, hydrophilic amino acids, basic amino acids, acidic amino acids, and aromatic amino acids.

### Claim 9 (depends on 1)

The composition of claim 1, wherein POLY is a Pluronic, and AA is selected from the group consisting of Leucine, Methionine, Lysine, Aspartic acid, Asparagine, Tyrosine, Serine, and Cysteine.

### Claim 10 (depends on 1)

The composition of claim 1, wherein the combination is two or more of formula (I) mixed, wherein POLY is a Pluronic F-127 (PF127), and AA is selected from the group consisting of Lysine, Serine, and Cysteine.

### Claim 11 (depends on 1)

The composition of claim 1, furthering comprising a metal ion.

### Claim 12 (depends on 11)

The composition of claim 11, wherein the metal ion is one or more selected from the group consisting of Na+, +, Ag+, Cu+2, Mg+2, Ca+2, Zn+2, Al+3, Fe+3, Se+4, and Ti+4.

### Claim 13 (depends on 1)

The composition of claim 1, further comprising a pharmaceutically active agent.

### Claim 14 (depends on 13)

The composition of claim 13, wherein the pharmaceutically active agent is selected from the group consisting of anticancer drugs, antibiotics, hemostatic agents, steroids, non-steroidal anti-inflammatory drugs, hormones, analgesics, and anesthetics.

### Claim 15 (depends on 1)

Use of the composition of claim 1 for the prevention of postoperative tissue adhesion and drug delivery.